Ethylone
3,4-methylenedioxy-N-ethylcathinone
Viewing r1 — Apr 26, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Ethylone (3,4-methylenedioxy-N-ethylcathinone) — also known as bk-MDEA — is a synthetic stimulant-entactogen of the cathinone class. It is a structural relative of methylone and the cathinone-class counterpart of MDEA. It blocks monoamine reuptake and actively releases serotonin, producing combined stimulant and emotionally opening effects.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
methylone, mephedrone, MDMA +2 moremethylone, mephedrone, MDMA, amphetamine, cocaine show less
Ethylone emerged through clandestine chemical research around 2009–2010, first documented in a published metabolism review that same year.[3] It spread as part of the global "bath salts" wave of designer stimulants, appearing in US drug tests by early 2011.[4] It is now Schedule I in the United States and internationally controlled under the UN Convention on Psychotropic Substances.
Subjective effects include euphoria, enhanced sociability, emotional warmth, heightened energy, sensory brightness, and wakefulness.[5] The experience sits between a clean stimulant push and a mild MDMA-like emotional openness — shorter and less emotionally deep, with a prominent energy edge. Jaw clenching, anxiety, insomnia, and low mood in the days after use are common unsought effects.
No physical dependence data exist for ethylone, and no lethal dose or human overdose study has been published.[6][7] The primary dangers are cardiovascular stress and serotonin overload — both amplified by high doses or combination with other serotonin-raising drugs; the serotonin-dominant profile predicts lower compulsive redosing drive than more dopamine-focused cathinones.[8] The evidence base rests almost entirely on lab studies and structural analogy; no human clinical trials have been conducted.
History[edit]
Discovery
Ethylone is the N-ethyl homolog of methylone, which was first synthesized by Peyton Jacob III and Alexander Shulgin in the mid-1990s.[9] Ethylone itself has no documented original synthesis — it arose through clandestine structural variation, replacing methylone's N-methyl group with an N-ethyl group. No peer-reviewed publication covers its original creation.
Market emergence
Ethylone entered designer drug markets between 2009 and 2013 as part of the "bath salts" wave. Its earliest scientific mention appears in Meyer and Maurer's 2010 metabolism review under the name bk-MDEA,[3] and it was detected in US urine specimens beginning in February 2011.[4]
Scheduling
International controls followed quickly. The UK controlled all substituted cathinones as Class B in 2010; Australia banned ethylone in 2014.[5] The UN added it to Schedule II in March 2017,[10] and the US DEA issued a specific Schedule I listing in June 2020.[11]
The name ethylone follows systematic cathinone nomenclature: the "-one" suffix marks the beta-keto group, while "ethyl-" distinguishes it from Methylone. The alternate name bk-MDEA encodes the structural relationship — "bk" for beta-keto, "MDEA" for the non-keto parent compound. Ethylone has no widely recognized street names; it circulated primarily under its chemical identifiers in online research chemical markets and was frequently sold in "bath salt" blends without specific labeling.
Chemistry[edit]
Structural class
Ethylone is a methylenedioxy-substituted synthetic cathinone — a structural family defined by a beta-keto group on the side chain and a 3,4-methylenedioxy ring on the aromatic core (molecular formula C₁₂H₁₅NO₃, molecular weight 221.25 g/mol).
It is the direct beta-keto structural analog of MDEA and the N-ethyl homolog of methylone, differing from methylone by a single methylene unit on the amine nitrogen — a change that produces measurable differences in transporter activity.[2] The methylenedioxy ring is the same structural feature found in MDMA, which accounts for the entactogenic character shared across the methylenedioxy cathinone group.[10]
Pharmacology[edit]
Mechanism of action
Ethylone works through two simultaneous actions. It blocks the recycling of dopamine, norepinephrine, and serotonin — leaving them active in the synapse longer — while also actively pushing serotonin out of nerve terminals via the SERT.[1][2] The stimulant component comes from the reuptake-blocking action; the emotional warmth and sociability come from the active serotonin release.
Because serotonin release dominates over dopamine effects, ethylone drives less compulsive seeking behavior than cathinones that target dopamine more strongly — though the dopamine reuptake inhibitor still confers meaningful abuse potential.[8]
Pharmacokinetics
No human pharmacokinetic data have been published for ethylone. Based on the closely related methylone, oral onset likely occurs within 30–90 minutes and the parent compound clears with a half-life of roughly 60–90 minutes.[12] Metabolism has been mapped in human liver microsomes, with breakdown products serving as the primary markers in forensic urine testing.[13][4]
Neuroscience[edit]
Where it acts
Ethylone raises both dopamine and serotonin in the brain simultaneously. Dopamine elevation in the brain's reward circuit drives energy, motivation, and reinforcement.[9] Serotonin release across cortical and emotional circuits produces the warmth and sociability that distinguish entactogens from pure stimulants.
Why it matters
Dopamine and serotonin pull in different directions. Dopamine drives "wanting" — motivation and compulsive seeking. Serotonin shapes "liking" — the hedonic quality of an experience — and may actively dampen the dopamine wanting signal.[8] Ethylone's serotonin-leaning profile predicts an experience weighted toward warmth and connection rather than compulsive stimulation.
Critical questions about ethylone remain unanswered. The closely related methylone does not cause long-term serotonin depletion with repeated use[9] — whether ethylone shares this relative safety is unknown. No human dosing data exist; dose ranges circulating in harm reduction communities derive entirely from uncontrolled reports.safety citation needed
Subjective Effects[edit]
Ethylone produces a hybrid experience where stimulant energy and emotional warmth run together. The stimulant edge — focus, motivation, wakefulness — sits alongside an entactogenic softening: lowered emotional barriers, heightened sociability, and sensory richness. Social settings draw out the warmth; quieter, task-focused settings emphasize the stimulation.
Users familiar with MDMA generally find ethylone shorter, less emotionally immersive, and more energy-forward — the warmth is present but shallower. Compared to methylone, the two occupy similar pharmacological territory; both sit well removed from the purely stimulant character of dopamine-focused cathinones like MDPV.
Effect Grid
At common doses (125–200 mg oral), the full entactogenic-stimulant experience manifests. Euphoria is prominent, accompanied by enhanced sociability, emotional openness, and empathogenic warmth toward others. Music enhancement becomes pronounced, and touch enhancement is clearly present. Sensory perception is heightened across modalities — visual brightening, mild visual haze, and intensified auditory experience. Thought acceleration is marked, with increased motivation and engagement.
Physically, stimulation is strong: elevated heart rate, bruxism (jaw clenching), appetite suppression, wakefulness, and sexual arousal enhancement. Temperature dysregulation becomes a genuine concern — users feel warm and may sweat.
The experience commits the user for approximately 2–4 hours of active effects, with an additional period of residual stimulation and mood shift. Sleep is impossible during active effects.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Light sensitivity · Sound sensitivity · Brightness alteration · Color alteration
Body high · Dry mouth · Pupil dilation · Spontaneous body sensations · Dehydration sensation · Excessive sweating · Bruxism · Insomnia · Muscle tension · Physical fatigue · Restlessness · Tactile euphoria · Sexual arousal enhancement · Heart rate perception changes · Laughter fits · Tingling / electric sensations · Vibrations / buzzing · Bodily lightness · Dizziness · Headache · Nausea · Respiratory stimulation · Increased urination · Abnormal heartbeat · Nystagmus (eye wobbles)
Spontaneous body sensations · Dehydration sensation · Excessive sweating · Bruxism · Insomnia · Muscle tension · Physical fatigue · Restlessness · Tactile euphoria · Sexual arousal enhancement · Heart rate perception changes · Laughter fits · Tingling / electric sensations · Vibrations / buzzing · Bodily lightness · Dizziness · Headache · Nausea · Respiratory stimulation · Increased urination · Nystagmus (eye wobbles)
Openness enhancement · Motivation suppression · Aesthetic enhancement · Humor enhancement · Immersion enhancement · Introspection enhancement · Creativity enhancement · Motivation enhancement · Analysis suppression · Cognitive flexibility · Memory suppression · Novelty enhancement · Suggestibility enhancement · Thought connectivity · Analysis enhancement · Focus enhancement · Information processing enhancement · Language enhancement · Thought deceleration · Cognitive impairment · Memory fragmentation
Humor enhancement · Immersion enhancement · Introspection enhancement · Creativity enhancement · Motivation enhancement · Analysis suppression · Cognitive flexibility · Memory suppression · Novelty enhancement · Thought connectivity · Analysis enhancement · Focus enhancement · Information processing enhancement · Language enhancement · Thought deceleration · Cognitive impairment · Memory fragmentation
Irritability · Anxiety · Anhedonia · Anxiety suppression · Dysphoria · Emotional lability · Simultaneous emotions · Catharsis
Dysphoria · Emotional lability · Simultaneous emotions · Catharsis
Communication enhancement · Emotional susceptibility · Craving · Flow state · Boundary dissolution
Boundary dissolution
Timeline
First alerts emerge as mild restlessness and subtle mood lift. Physical awareness increases slightly — a faint warmth or tingling sensation may be noticed.
Stimulation builds progressively with rising heart rate, jaw tension onset, and emerging sociability. Sensory enhancement begins — music sounds richer, tactile sensitivity increases.
Maximum entactogenic and stimulant effects: pronounced euphoria, emotional openness, enhanced sociability, strong sensory intensification. Bruxism, tachycardia, and temperature dysregulation are at their most prominent.
Effects sustain at reduced intensity. Entactogenic warmth persists while stimulant edge softens. Cognitive clarity begins to return though sensory enhancement remains.
Gradual return toward baseline. Residual stimulation and mild mood elevation continue. Physical effects (jaw tension, elevated heart rate) diminish.
Residual effects include mild fatigue, subdued mood, and possible irritability as monoamine levels normalize. Some users report lingering warmth and reflectiveness; others experience low mood and anxiety.
⚠ Do not drive or operate machinery until after a full night of sleep, as residual stimulant effects and fatigue may impair reaction time and judgment.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- methylone · mephedrone · MDMA
Toxicity
Acute toxicity
No lethal dose, animal toxicology study, or human overdose case report has been published for ethylone. This reflects its relative rarity in surveillance data — not confirmed safety.
Class-level risks for synthetic cathinones include rapid heart rate, elevated blood pressure, and rare heart attack,[7] plus serotonin syndrome at high doses — dangerous overheating, metabolic acidosis, and muscle breakdown.[6][14]
Heart and circulation
Elevated heart rate and blood pressure are expected consequences of blocking dopamine and norepinephrine clearance. Irregular heartbeat has been reported.[5] Heart attack has been documented with cathinone class agents in rare cases.[7]
Serotonin toxicity
At high doses or combined with other serotonergic agents, ethylone carries risk of serotonin syndrome — a potentially fatal condition involving dangerous overheating, muscle rigidity, and altered consciousness. No specific antidote exists; treatment is supportive.[6][7]
Overdose can present with severe headache, dangerously high body temperature, dehydration, agitation, hallucinations, psychosis, and seizures; ethylone can cause death.[5]
After-effects
The days after use commonly bring anxiety, fatigue, insomnia, depression, and irritability.[5] These follow predictably from temporary serotonin depletion after serotonin release.
Psychological risks
No ethylone-specific psychiatric data exist. Across the synthetic cathinone class, documented adverse effects include agitation, anxiety, paranoia, hallucinations, acute psychosis, and seizures.[15]
Ethylone's serotonin-dominant profile means psychiatric risks lean toward mood instability and anxiety rather than the dopamine-driven paranoid psychosis seen with more stimulant-focused cathinones. Chronic use can still produce persistent paranoid ideation.[15]
Tolerance & dependence
No published tolerance or dependence data exist for ethylone. Tolerance is expected with repeated use through transporter desensitization, with cross-tolerance plausible to other stimulants and serotonin-releasing agents.
Structural analogs — methylone, butylone, pentylone — are reliably self-administered in animal models.[16] Ethylone's serotonin-dominant profile predicts lower reinforcing effectiveness than dopamine-selective cathinones, but the dopamine component still confers meaningful abuse potential.[8][1]
Drug interactions
Tramadol blocks the SERT.[17][18] Combined with ethylone's serotonin-releasing activity,[2] this creates additive serotonergic burden with a direct pathway to serotonin syndrome.
MAOIs block serotonin breakdown. Combined with ethylone's serotonin release, dangerous — potentially fatal — serotonin accumulation results.
SSRIs and SNRIs add serotonergic load and may also blunt ethylone's entactogenic effects by occupying the serotonin transporter.
MDMA and other serotonergic entactogens produce additive serotonergic burden with elevated risk of overheating and serotonin syndrome.[1]
Alcohol may mask the perceived stimulant effect, increasing dose escalation risk; combined cardiovascular stress is unpredictable.
Contraindications
Heart conditions: Elevated heart rate and blood pressure are class effects. Pre-existing cardiovascular disease increases acute cardiac event risk.[7]
Psychotic disorders: Synthetic cathinones produce paranoid ideation, hallucinations, and acute psychosis.[15] Pre-existing psychotic vulnerability substantially amplifies this risk.
Concurrent MAOI use: Absolute contraindication — life-threatening serotonin syndrome risk.
Concurrent serotonergic medications (SSRIs, SNRIs, tramadol): Serotonin syndrome risk via additive serotonergic load.[17][18]
Seizure disorders: Seizures are documented across the cathinone class.[15]
Pregnancy and breastfeeding: No reproductive toxicity data exist. Stimulant and serotonergic activity represent theoretical risks to fetal development.safety citation needed
Harm Reduction[edit]
Forms & Identification
Ethylone typically appears as white powder or clear crystals.[5] Synthetic cathinones are visually indistinguishable from one another; reagent testing can narrow possibilities but cannot confirm identity. Laboratory analysis through a drug checking service is the only reliable identification method.
Cathinone products are frequently mislabeled or contain mixtures. Testing is not optional — it is the minimum threshold for informed dosing.
Guidelines
- Test every batch with a reagent kit and, where available, a drug checking service. Visual inspection cannot distinguish ethylone from more dangerous cathinones.
- Start with a low dose and wait at least 90 minutes before considering redosing. Oral onset can be slow, and premature redosing is the most common path to excessive stimulation.
- Weigh doses with a milligram-precision scale. Volumetric estimation of powder is unreliable.
- Stay hydrated but avoid overhydration — sip water steadily rather than drinking large amounts. Serotonergic stimulants can impair the body's fluid regulation.
- Eat a light meal beforehand. Stimulant appetite suppression combined with physical activity increases dehydration and exhaustion risk.
- Have a sober, trusted person present who knows what has been taken.
Set & Setting
Ethylone's effects are strongly context-dependent. Social environments amplify the entactogenic warmth; isolated settings may foreground stimulant anxiety. A comfortable, familiar environment with trusted people reduces the likelihood of anxiety escalation.
The duration is relatively short, but the stimulant tail may extend beyond the primary effects. Adequate time for wind-down and sleep before obligations matters.
Aftercare & integration. The days following ethylone use commonly involve low mood, fatigue, irritability, and disrupted sleep — a predictable consequence of temporary serotonin depletion. These effects typically resolve within 2–4 days.
- Sleep: Prioritize rest. The stimulant tail may make the first night difficult; avoid using additional substances to force sleep.
- Nutrition: Eat balanced meals even if appetite is reduced. Tryptophan-rich foods support natural serotonin recovery.
- Activity: Light exercise can improve mood during the recovery window. Avoid intense exertion for 24–48 hours.
- Reflection: If the experience produced emotional material — particularly if entactogenic effects were prominent — journaling or conversation with a trusted person can help process it.
If low mood, anxiety, or sleep disruption persists beyond a week, consult a healthcare provider.
Recovery & Support
Ethylone's serotonin-dominant profile may produce lower compulsive redosing drive than dopamine-selective stimulants, but repeated use still carries dependence risk. Warning signs include escalating frequency, difficulty maintaining commitments, using alone, and continuing despite negative consequences.
Support resources include SAMHSA's National Helpline (1-800-662-4357), local drug and alcohol services, and peer support communities. Cognitive behavioral therapy has established efficacy for stimulant use disorders. Early intervention produces better outcomes.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
Most ethylone experiences involve manageable discomfort. The following signs require immediate medical help:
- Chest pain, crushing pressure, or sudden sharp pain in the left arm or jaw
- Seizures or uncontrollable muscle rigidity
- Body temperature hot enough to feel through clothing — dangerous overheating
- Loss of consciousness or unresponsiveness
- Severe confusion, psychosis, or self-harm behavior
- Irregular or very rapid heartbeat that does not slow with rest
Immediate steps
- 1. Call emergency services immediately if any of the above are present.
- 2. Move the person to a cool, quiet area. Remove excess clothing if overheating.
- 3. If unconscious but breathing, place in the recovery position (on their side, airway clear).
- 4. Do not restrain the person unless they are in immediate physical danger.
- 5. Do not induce vomiting.
- 6. Stay with them until help arrives.
What to tell the dispatcher
State what was taken (ethylone or synthetic cathinone), the approximate amount and time, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency — do not let fear of legal consequences delay the call.
Legal Status[edit]
Ethylone is controlled in all major jurisdictions, following scheduling actions between 2010 and 2020 that targeted the synthetic cathinone class broadly.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International (UN) | Schedule II — 1971 Convention on Psychotropic Substances | Added March 2017 at the 60th Session of the Commission on Narcotic Drugs; CAS 1112937-64-0[10] |
| United States | Schedule I (Controlled Substances Act) | Specific listing effective June 8, 2020; CSA code 7547. Previously controlled under the Federal Analogue Act as a positional isomer of butylone[11] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | All substituted cathinones controlled via generic ban, effective 2010 |
| Australia | Controlled substance (state-based) | Banned in Queensland, New South Wales, South Australia, and Victoria[5] |
| WADA | Specified stimulant | Prohibited in competition; synthetic cathinone class[19] |
Scheduling status changes over time. This table reflects known classifications as of 2026 and does not constitute legal advice.
references
- [1] ^abcdSimmler LD, Buser TA, Donzelli M, et al. (2012) Pharmacological characterization of designer cathinones in vitro — British Journal of Pharmacology doi:10.1111/j.1476-5381.2012.02145.x
- [2] ^abcdEshleman AJ, Wolfrum KM, Reed JF, Kim SO, Swanson T, Johnson RA, Janowsky A (2017) Structure-Activity Relationships of Substituted Cathinones, with Transporter Binding, Uptake, and Release — Journal of Pharmacology and Experimental Therapeutics doi:10.1124/jpet.116.236349
- [3] ^abMeyer MR, Maurer HH (2010) Metabolism of designer drugs of abuse: an updated review — Current Drug Metabolism PMID:20540700
- [4] ^abcUralets V, Rana S, Morgan S, Ross W (2014) Testing for designer stimulants: metabolic profiles of 16 synthetic cathinones excreted free in human urine. — Journal of Analytical Toxicology doi:10.1093/jat/bku021
- [5]
- [6] ^abcDebruyne D, Loilier M, Cesbron A, Le Boisselier R, Bourgine J (2014) Emerging drugs of abuse: current perspectives on substituted cathinones — Substance Abuse and Rehabilitation doi:10.2147/sar.s37257